Skip to main content
Tessa NewsLink
Paste a health news link, or browse

Source study found

Story checked

Ocrelizumab Raises Infection Risk in Older Adults With MS (opens in a new tab)

medscape.com · 2026-10-06

Short answerEvidenceSource

Short answer

Mixed

Mixed.

The claims we could check match the study, but some claims were not covered by the evidence reviewed.

  • 2 supported
  • 4 not covered

Checked against the study summary. The full text wasn't available, so some details couldn't be settled either way.

Share this check

Follow the evidence trail
1
2

NewsLink checks it

Mixed

Every claim we could check holds up. Two of six claims match the study. This overall rating is based only on the claims we could check. Four claims the study doesn't address.

  • 2 supported
  • 4 not covered
Open claim evidence
3
Then inspect each claim

Evidence layer

Claim by claim

Each claim gets a verdict. Expand it to see the evidence directly below.

6 claims in this story

Showing all 6 claimsChoose a verdict to focus the list.

Claim 1 of 6Not coveredUrinary tract infections emerged as the leading type of infection observed in the cohort.View evidenceHide evidence

Why this verdict

The abstract-level profile supports that urinary tract infections drove most of the observed female-versus-male infection difference, but it does not state that UTIs were the leading or most common infection type in the overall cohort. That claim may require full-text subtype tables or results beyond the abstract.

1

Study evidence

Higher disability and greater comorbidity were independently associated with increased risk of both infections and infection-related hospitalizations in the cohort.

“Higher disability and comorbidity independently increased the risk of both outcomes.”
Claim 2 of 6Not coveredAfter adjustment, ocrelizumab exposure was associated with higher rates of infection-related hospitalization and overall infection, while higher comorbidity burden and higher baseline disability also predicted greater risk.View evidenceHide evidence

As statedIRR 1.67 for hospitalization; IRR 1.42 for infection; comorbidity IRR 1.34/1.21; disability IRR 1.56/1.16

Why this verdict

The abstract-level profile supports the adjusted ocrelizumab associations and qualitatively supports higher disability and comorbidity as independent risk factors for both infections and infection-related hospitalizations. However, the specific comorbidity and disability IRRs stated in the story are not provided in the abstract-level profile, so the full magnitude claim is not verifiable at this evidence depth.

1

Study evidence

Ocrelizumab exposure (≥600 mg IV) was associated with a higher rate of infection-related hospitalizations compared with unexposed older adults with MS after IPTW-adjusted negative binomial modeling.IRR 1.67 (95% CI 1.15–2.43; p = 0.008)

“a retrospective cohort study was performed, analyzing the electronic medical records, June 2017-January 2026”
2

Study evidence

Higher disability and greater comorbidity were independently associated with increased risk of both infections and infection-related hospitalizations in the cohort.

“Higher disability and comorbidity independently increased the risk of both outcomes.”
Claim 3 of 6Not coveredWomen in the cohort had a higher infection rate than men, and most of that difference was attributed to urinary tract infections; in a UTI-only model, both ocrelizumab exposure and female sex were independently associated with higher UTI risk.View evidenceHide evidence

As statedwomen 36% higher infection rate; 91.46% of disparity attributed to UTIs; UTI IRR 1.94 for ocrelizumab and 1.97 for female sex

Why this verdict

The abstract-level profile supports that female sex was associated with higher infection risk, with IRR 1.36, and that UTIs accounted for 91.46% of the observed sex difference. It does not report a UTI-only model or the stated UTI-specific IRRs for ocrelizumab exposure and female sex, so that portion is not verifiable from the abstract-level evidence.

1

Study evidence

Higher disability and greater comorbidity were independently associated with increased risk of both infections and infection-related hospitalizations in the cohort.

“Higher disability and comorbidity independently increased the risk of both outcomes.”
Claim 4 of 6Not coveredThe article notes important limitations, including the retrospective design, inconsistent follow-up, possible immortal time bias, missing baseline disability data, and limited generalizability from a single predominantly White academic center.View evidenceHide evidence

Why this verdict

Several limitations named in the story are supported or closely aligned with the abstract-level profile, including retrospective single-center design, unequal follow-up, and limited generalizability from a predominantly White cohort. However, the profile does not verify possible immortal time bias or substantial missing baseline disability data at abstract depth, so the full limitation list cannot be confirmed here.

1

Study evidence

Ocrelizumab exposure (≥600 mg IV) was associated with a higher rate of infection-related hospitalizations compared with unexposed older adults with MS after IPTW-adjusted negative binomial modeling.IRR 1.67 (95% CI 1.15–2.43; p = 0.008)

“a retrospective cohort study was performed, analyzing the electronic medical records, June 2017-January 2026”
2

Study evidence

Higher disability and greater comorbidity were independently associated with increased risk of both infections and infection-related hospitalizations in the cohort.

“Higher disability and comorbidity independently increased the risk of both outcomes.”
Claim 5 of 6SupportedAmong adults aged 55 years or older with multiple sclerosis, those exposed to ocrelizumab had higher rates of infection-related hospitalization and infection overall than those never exposed to any B-cell-depleting therapy.View evidenceHide evidence

As statedinfection-related hospitalization IRR 1.67; overall infection IRR 1.42

Why this verdict

The abstract-level profile directly supports an adjusted association between ocrelizumab exposure and higher infection-related hospitalization rates and overall infection rates in adults aged ≥55 years with MS, with the stated IRRs of 1.67 and 1.42. The claim is framed associationally rather than causally, which matches the observational retrospective cohort evidence.

1

Study evidence

Ocrelizumab exposure (≥600 mg IV) was associated with a higher rate of infection-related hospitalizations compared with unexposed older adults with MS after IPTW-adjusted negative binomial modeling.IRR 1.67 (95% CI 1.15–2.43; p = 0.008)

“a retrospective cohort study was performed, analyzing the electronic medical records, June 2017-January 2026”
Claim 6 of 6SupportedThe study was a retrospective cohort analysis using electronic medical records from Massachusetts General Hospital, including 1600 participants with MS aged 55 years or older.View evidenceHide evidence

As stated1600 participants; 800 exposed and 800 unexposed

Why this verdict

The profile states that the study was a single-center Massachusetts General Hospital retrospective cohort using electronic medical records and included 1600 adults aged ≥55 years with MS, split into 800 ocrelizumab-exposed and 800 unexposed to B-cell-depleting therapy.

1

Study evidence

Ocrelizumab exposure (≥600 mg IV) was associated with a higher rate of infection-related hospitalizations compared with unexposed older adults with MS after IPTW-adjusted negative binomial modeling.IRR 1.67 (95% CI 1.15–2.43; p = 0.008)

“a retrospective cohort study was performed, analyzing the electronic medical records, June 2017-January 2026”
Then look for missing context

Context layer

What the story left out

Important study details the story did not include.

  • Important limitation: observational non-randomized design with potential residual confounding despite IPTW adjustment.

    The story mentions retrospective design and uses associational framing, but its listed caveats do not explicitly acknowledge residual confounding despite adjustment, an interpretation-changing limitation for observational safety comparisons.

    From Retrospective cohort (EMR-based); Retrospective EMR cohort; covariate association modeling (negative binomial regression

6 things the story did carry across
  • Primary design and comparison: a single-center Massachusetts General Hospital EMR-based retrospective cohort of 1600 adults aged ≥55 years with MS, comparing 800 ocrelizumab-exposed patients with 800 patients never exposed to B-cell-depleting therapies.
  • Main adjusted finding: ocrelizumab exposure was associated with higher rates of infection-related hospitalization and overall infection, with IRRs 1.67 and 1.42, respectively.
  • Secondary risk-factor findings: higher disability, higher comorbidity, and female sex were associated with higher infection risk; higher disability and comorbidity were also associated with infection-related hospitalization risk.
  • UTI-related finding: the abstract-level paper evidence says UTIs accounted for 91.46% of the observed sex difference in infection rates, but does not establish at abstract depth that UTIs were the most common infection type overall or provide UTI-only model IRRs.
  • Important limitation: unequal median follow-up between groups, 3.5 years in the ocrelizumab group versus 8.2 years in the unexposed group.
  • Important limitation: single academic center and predominantly White cohort, limiting generalizability.
Then read the study layer

Study layer

Study at a glance

Scan the study first. Expand only the parts you want to inspect.

Pieces of work

2

Evidence read

study summary

Lead result

secondary data

1Lead resultsecondary dataCompare rates of infections and infection-related hospitalizations in adults aged ≥55 years with MS treated with ocrelizumab versus similar older adults with MS unexposed to B-cell depleting therapies, using EMR-derived retrospective cohort data.Retrospective cohort (EMR-based)Expand

In plain English

Retrospective single-center cohort study (Massachusetts General Hospital EMR, June 2017–Jan 2026) comparing 800 adults ≥55 years with MS who received ≥600 mg ocrelizumab IV to 800 older adults with MS never treated with B-cell depleting therapies. Infection and infection-related hospitalization rates were modeled using inverse probability of treatment weighting and negative binomial regression with person-time offsets. After adjustment, ocrelizumab exposure was associated with higher rates of infection-related hospitalization and overall infections; female sex (driven mainly by urinary tract infections), greater disability, and greater comorbidity were associated with higher infection risk.

Key findings

  • Ocrelizumab exposure (≥600 mg IV) was associated with a higher rate of infection-related hospitalizations compared with unexposed older adults with MS after IPTW-adjusted negative binomial modeling.IRR 1.67 (95% CI 1.15–2.43; p = 0.008)
  • Ocrelizumab exposure was associated with a higher overall infection rate compared with unexposed older adults with MS after adjustment.IRR 1.42 (95% CI 1.20–1.68; p < 0.001)
“a retrospective cohort study was performed, analyzing the electronic medical records, June 2017-January 2026”
What this piece can’t prove
  • Single-center (Massachusetts General Hospital) retrospective EMR-based cohort study.
  • Cohort predominantly White (93.5%), which may limit generalizability.
  • Non-randomized observational design; IPTW used for adjustment but potential for residual confounding remains (not quantified in abstract).

2 further details could not be confirmed from the summary.

2secondary dataIdentify patient factors (e.g., disability, comorbidity, sex) associated with infection and infection-related hospitalization risk, including characterization of the observed sex difference as largely driven by urinary tract infections.Retrospective EMR cohort; covariate association modeling (negative binomial regression with IPTW and person-time offsets)Expand

In plain English

Within the same EMR-based retrospective cohort of older adults with MS (n=1600), multivariable risk-factor analyses found that higher disability and greater comorbidity were independently associated with increased rates of both infections and infection-related hospitalizations; female sex was associated with higher infection rates (IRR 1.36, 95% CI 1.12-1.64, p=0.002), and the observed sex difference in infections was reported to be driven largely by urinary tract infections (UTIs), which accounted for 91.46% of the sex difference.

Key findings

  • Higher disability and greater comorbidity were independently associated with increased risk of both infections and infection-related hospitalizations in the cohort.
  • Female sex was associated with a higher infection rate.IRR 1.36 (95% CI 1.12–1.64); p = 0.002
“Higher disability and comorbidity independently increased the risk of both outcomes.”
What this piece can’t prove
  • Observational, single-center EMR cohort design may be subject to residual confounding and misclassification of exposures, covariates, and infection outcomes.
  • Cohort demographics reported in abstract (median ages, 69.4% female, 93.5% White) may limit generalizability to more diverse populations.
  • Differing median follow-up times between exposure groups (3.5 vs 8.2 years) could affect incidence estimates despite use of person-time offsets.

1 further detail could not be confirmed from the summary.

Finally, the search trail

Method layer

NewsLink found the paper. Tessa takes you deeper.

NewsLink checks the story. Tessa is where you inspect the paper, authors, evidence, and research context.

Papers considered

The selected paper, plus nearby candidates.

PubMed, Europe PMC, Crossref · 37 candidate papers

And 31 more candidates considered.